BostonGene has introduced new liquid biopsy, immunoprofiling and spatial proteomics solutions, which have been Clinical Laboratory Improvement Amendments-validated and College of American Pathologists-accredited.
The expanded portfolio of tests will advance the development of novel assays, analytical tools and pipelines to bring precision medicine to patients.
Go deeper with GlobalData
The new solutions combine various artificial intelligence-driven molecular and immune profiling techniques to analyse tumour, microenvironment and host immunity.
These additions, along with the BostonGene Tumor Portrait test, will enhance the efficiency of research and development (R&D) efforts and clinical trials.
BostonGene chief medical officer Dr Nathan Fowler said: “BostonGene’s innovative solutions offer clinicians and researchers evidence-based recommendations to guide clinical decision-making.
“Leveraging big data through BostonGene tests provides an unprecedented understanding of a patient’s molecular profile, including the critical drivers of each tumour, immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies and recommended therapies necessary for personalised treatment selection.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe liquid biopsy assay facilitates high-sensitivity identification of clinically relevant changes in genes to predict and monitor disease progression and treatment response. It covers pan-cancer biomarkers and studies 216 genes, including 200 genes with complete exonic (coding) coverage.
Precise testing results will be offered by the company’s error reduction algorithms and hematopoietic mutation filtration.
The company’s immunofluorescence assay offers a comprehensive overview of tumour cells, stromal and vascular components, immune active and suppressive cell infiltration, as well as analytics of tissue architecture based on cell-to-cell interactions.
The immunoprofiling uses a single tube of blood to detect surrogate biomarkers for successful patient selection in a clinical trial.
It also provides monitoring of disease progression and treatment response, assists in immunotherapy treatment and provides information on a patient’s immune-related conditions.
